UK company Xenova has created a new subsidiary, Xenova Discovery, whichis to be headed by David Oxlade as chief executive. He joins the firm from Syva, a division of Behring Diagnostics.
The staff, business and assets of Xenova's discovery division have been handed over to Xenova Discovery, which will assume responsibility for discovery-related management of the group's existing collaborative agreements. Michael Moore, formerly research director of the division, is appointed research director of the new company.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze